Cargando…
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit o...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939993/ https://www.ncbi.nlm.nih.gov/pubmed/27462141 http://dx.doi.org/10.2147/DDDT.S104225 |